Back
MQDB
Macquarie Dynamic Bond Active ETF
π¦πΊ ASX
π Overview
π Performance
π Holdings
π° Distributions
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
+ 4.24%
Annual Growth
2 years average annual capital growth
π°
2.11%
Annual distribution yield
Based on the most recent distribution
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
1
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
MQDB.AX was created on 2002-09-30 by Macquarie. The fund's investment portfolio concentrates primarily on broad credit fixed income. The Fund aims to generate attractive returns by dynamically investing in global fixed income instruments. It aims to provide diversification against equity risk as well as capital growth and some income
π Performance
Price History
+6.82%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ Top Holdings
Show moreTop holdings information is not yet available for this fund. For more information please visit the fund manager's website.
π° Distributions
Payouts
π° Annual Distribution Yield*
2.11%
π° Annual Distribution Earnings Per $1,000 invested**
$21.13
π° Most Recent Distribution Franked Percentage Estimate
0.00%
π° Average Distribution Franked Percentage Estimate
0.00 %
π° Distribution reinvestment
* Based on the most recent distribution
** Calculated by multiplying the most recent distribution yield by $1,000
Estimate your distribution
If you held
$
of MQDB, your last distribution payment(s) would have been:
$ 83.57
on Wed Apr 16 2025
$ 76.15
on Fri Jan 17 2025
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Distribution History
1Y
5Y
10Y
Graph
Table
Year
Yearly Distribution Earnings Per Share
Franking Estimate
2025
$0.17
0.00%
2024
$0.06
0.00%
2023
$0.00
0.00%
2022
$0.00
0.00%
2021
$0.00
0.00%
2020
$0.00
0.00%
2019
$0.00
0.00%
2018
$0.00
0.00%
2017
$0.00
0.00%
2016
$0.00
0.00%
π΅ Costs
πΌ
0.61%
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$10.81
π° Price To Earnings Ratio
0.00
π° Price To Book Ratio
0.00
π° Leveraged
No
π° Inverse
No
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in MQDB
1
π Total Capital Earnings
N/A
π Average investment frequency
22 weeks
π΅ Average investment amount
$3,000
β° Last time a customer invested in MQDB
84 days
MQDB investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50%
50k - 100k
Less than 50k
50%
πΆ Age of investors
18 - 25
26 - 34
35 - 90
100%
π Legal gender of investors
Female
Male
100%
Pearlers who invest in MQDB also invest in...
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
π Performance (5Yr p.a)
22.05%
π Share price
$62.78 AUD
π HIGH PRICE GROWTH
πΊπΈ UNITED STATES
CSL
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 30,398 full-time employees. The Companyβs areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Companyβs segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
π Performance (5Yr p.a)
-3.05%
π Share price
$241.09 AUD
ποΈ SOCIALLY AWARE
βοΈ HIGH GOVERNANCE
𧬠BIOTECHNOLOGY
Macquarie Group Ltd. operates as a non-operating holding company. The company is headquartered in Sydney, New South Wales and currently employs 20,053 full-time employees. The company went IPO on 2007-11-05. The firm specializes in asset management, retail and business banking, wealth management, leasing and asset financing, market access, commodity trading, renewables development, specialist advice, access to capital and principal investment. Its segments include Macquarie Asset Management (MAM), Banking and Financial Services (BFS), Commodities and Global Markets (CGM) and Macquarie Capital. MAM segment provides investment solutions to clients across a range of capabilities in private markets and public investments. The BFS segment provides a range of personal banking, wealth management, and business banking products and services to retail clients, advisers, brokers, and business clients. The CGM segment is a global business offering capital and financing, risk management, market access, physical execution, and logistics solutions. Macquarie Capital segment offers advisory and capital raising services.
π Performance (5Yr p.a)
18.07%
π Share price
$229.82 AUD
π HIGH PRICE GROWTH
πΈ FINANCIALS
RMD
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. The company is headquartered in San Diego, California and currently employs 9,980 full-time employees. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. The company also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
π Performance (5Yr p.a)
8.99%
π Share price
$39.35 AUD
π©Ί HEALTH CARE
ποΈ SOCIALLY AWARE
π³ ENVIRONMENTAL
π HIGH PRICE GROWTH
QUAL.AX was created on 2014-10-29 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. Each Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.
π Performance (5Yr p.a)
17.11%
π Share price
$57.26 AUD
π€ TECHNOLOGY
π COMMUNICATIONS
π HIGH PRICE GROWTH
π GLOBAL
Want more shares? Try these...
MQEG.AX was created on 2024-05-13 by Macquarie. The fund's investment portfolio concentrates primarily on total market equity. The Fund provides exposure to a diversified portfolio of Global equities through securities listed, or expected to be listed, on global developed market exchanges
π Share price
$12.13 AUD
π€ TECHNOLOGY